Telerx, a leader in multi-channel engagement of consumers, patients, healthcare professionals and enterprise personnel, has launched CaseTrack360, a cutting-edge solution that utilizes Pegasystems Inc.’s Pega 7 unified platform to enable integrated customer journeys and improved healthcare outcomes. With CaseTrack360, Telerx and its clients will be able to engage customers through a central touch point during all phases of a product’s life cycle.
“The life sciences industry is facing unprecedented challenges and opportunities, including the sheer volume of data available. CaseTrack360 is a unique solution that delivers a 360 degree view with integrated workflows, advanced reporting, program launch support dashboards and trending to help better inform customers. These key insights can help drive actionable changes and process improvements,” said Mike Brannan, Telerx’s chief innovation officer.
CaseTrack360 addresses the need for proactive engagement as new regulatory guidelines emerge, and helps eliminate siloed systems that may offer little visibility into patient interactions across platforms. Additionally, the solution offers business process management functionality, commercial and medical domain features, and seamless integration with client databases.
“We are proud to provide the software platform for Telerx as it launches CaseTrack360, a novel, multi-channel customer engagement platform,” said Melonie Warfel, Global Director of Life Sciences at Pegasystems. “CaseTrack360 will help allow Telerx clients to quickly adapt to changing market conditions, regulatory mandates and customer needs.”
“We are fortunate to have a partner like Pegasystems, whose software applications enable us to deliver this advanced and completely scalable and customizable solution,” Brannan added. “We are confident that our clients will quickly recognize the benefits of CaseTrack360 technology — coupled with our proven approach of utilizing highly qualified representatives — offering insightful engagement each step of the way with the patient at the center of the solution.”
Telerx will first integrate CaseTrack360 into all of its patient support and adherence, product safety, and medical information case processing programs, with future plans to include sales and marketing, and digital and enterprise services as part of the overall solution.
To learn more about CaseTrack360, please visit:
http://www.telerx.com/solutions/healthcare/casetrack360/.
About Telerx
For more than 30 years, Telerx, a subsidiary of Merck & Co, Inc., has provided customer and patient care services to Fortune 1000 companies in the pharmaceutical, healthcare and consumer packaged goods industries. Using advanced technology, the company takes a customized approach to create highly successful customer experiences for millions of consumers, patients and healthcare providers each year and provide valuable insights that help drive better processes and outcomes. More than 90 percent of the company’s clients are FDA-regulated. Headquartered in Horsham, Pa., Telerx has additional contact centers in Pittston and Wilkes-Barre, Pa.; El Paso, Texas; Kings Mountain, N.C.; Morristown and Little Falls, N.J.; Hyderabad, India; Sofia, Bulgaria; and Dalian, China. For more information, visit Telerx.com or connect via Facebook,Twitter and LinkedIn.
About Merck
Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
About Pegasystems
Pegasystems (NASDAQ: PEGA) develops strategic applications for sales, marketing, service and operations. Pega’s applications streamline critical business operations, connect enterprises to their customers seamlessly in real-time across channels, and adapt to meet rapidly changing requirements. Pega’s Global 2000 customers include the world’s most sophisticated and successful enterprises. Pega’s applications, available in the cloud or on-premises, are built on its unified Pega 7 platform, which uses visual tools to easily extend and change applications to meet clients’ strategic business needs. Pega’s clients report that Pega gives them the fastest time to value, extremely rapid deployment, efficient re-use and global scale. For more information, please visit us at www.pega.com.
